Novartis Heart Drug Pelacarsen Fails Late-Stage Clinical Trial

A high-stakes Phase 3 trial for Novartis’s heart disease treatment, pelacarsen, has failed to meet its primary objective. The drug did not demonstrate a significant reduction in major cardiovascular events—such as strokes, heart attacks, and fatalities—when measured against a placebo, marking a setback for the company’s cardiac pipeline.

Today, 00:08· Money Talk· 357 reads

Despite the clinical failure, the medication successfully achieved its secondary goal of lowering lipoprotein(a) levels in patients. Shreeram Aradhye, Chief Medical Officer at Novartis, acknowledged the disappointment while framing the data as a contribution to the broader scientific grasp of how lipoprotein(a) levels interact with cardiovascular health outcomes.

Investors responded sharply to the news, pushing shares down 4.4% to $153.00 during after-hours trading on Friday. The company now faces a re-evaluation of its approach to cardiovascular risk management as it digests the study results.

Novartis Heart Drug Pelacarsen Fails Late-Stage Clinical Trial

Comments (0)